N/A
N=65
Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2
ARDS · Mechanical Ventilation Complication · Ventilator-Induced Lung Injury
Bottom Line
View on ClinicalTrials.gov: NCT04174313 ↗Enrolled (actual)
65
Serious AEs
56.9%
Results posted
Aug 2021
Primary outcome: Primary: Number of Participants Who Survived and Died — 1; 31; 14; 19 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- CT scan (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Hospital El Cruce
- Primary completion
- Mar 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Survived and Died |
1; 31; 14; 19 | — |
| PRIMARY Number of Patients With and Without Refractory Hypoxemia |
1; 14; 49; 1 | — |
| PRIMARY Number of Patients With Complications |
7; 19; 7; 18; 7; 10 | — |
Summary
The concept of Ventilator-induced Lung Injury Vortex (VILI vortex) has recently been proposed as a progressive lung injury mechanism in which the alveolar stress/strain increases as the ventilable lung "shrinks" (1). This positive feedback inexorably leads to the acceleration of lung damage, with potentially irreversible results. Little is known about the clinical aspects of this condition. Understanding its behavior could contribute to changing its potential devastating impact.
The objective of this study is to evaluate the incidence of VILI vortex in patients with acute respiratory syndrome (ARDS) secondary to COVID-19, to establish a connection between this phenomenon and mortality, and to identify the factors that have an impact on its development.
Eligibility Criteria
Inclusion Criteria: ARDS
-
Exclusion Criteria
Patients with do-not-resuscitate (DNR) orders and pregnant women. Cardiac arrest before ICU admission. Extra corporeal membrane oxygenation (ECMO) requirement within the first 24 h of ICU admission and chronic obstructive pulmonary disease with gold class 3 or 4, or home oxygen therapy
Data sourced from ClinicalTrials.gov (NCT04174313). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.